GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valiant Laboratories Ltd (NSE:VALIANTLAB) » Definitions » Net Current Asset Value

Valiant Laboratories (NSE:VALIANTLAB) Net Current Asset Value : ₹6.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Valiant Laboratories Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Valiant Laboratories's net current asset value per share for the quarter that ended in Mar. 2025 was ₹6.00.

The historical rank and industry rank for Valiant Laboratories's Net Current Asset Value or its related term are showing as below:

NSE:VALIANTLAB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.28   Med: 9.04   Max: 17.83
Current: 17.83

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Valiant Laboratories was 17.83. The lowest was 5.28. And the median was 9.04.

NSE:VALIANTLAB's Price-to-Net-Current-Asset-Value is ranked worse than
82.17% of 600 companies
in the Drug Manufacturers industry
Industry Median: 5.61 vs NSE:VALIANTLAB: 17.83

Valiant Laboratories Net Current Asset Value Historical Data

The historical data trend for Valiant Laboratories's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valiant Laboratories Net Current Asset Value Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Net Current Asset Value
15.69 10.69 8.77 27.55 6.00

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.55 - 14.27 - 6.00

Competitive Comparison of Valiant Laboratories's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valiant Laboratories's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Price-to-Net-Current-Asset-Value falls into.


;
;

Valiant Laboratories Net Current Asset Value Calculation

Valiant Laboratories's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(A: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1926.179-1665.474-0-0)/43.450
=6.00

Valiant Laboratories's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1926.179-1665.474-0-0)/43.450
=6.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valiant Laboratories  (NSE:VALIANTLAB) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Valiant Laboratories Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Valiant Laboratories's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Valiant Laboratories Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.

Valiant Laboratories Headlines

No Headlines